Have a feature idea you'd love to see implemented?
Let us know!
ARCT Arcturus Therapeutics Holdings Inc
Price (delayed)
$19
Market cap
$513.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.69
Enterprise value
$225.44M
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™
Highlights
Arcturus Therapeutics Holdings's debt has decreased by 4.1% YoY and by 2.5% QoQ
The net income has dropped by 190% year-on-year but it is up by 33% since the previous quarter
The company's EPS has shrunk by 188% YoY but it rose by 33% QoQ
ARCT's equity is down by 9% year-on-year and by 2% since the previous quarter
Key stats
What are the main financial stats of ARCT
Market
Valuations
Earnings
Shares outstanding
27.04M
Market cap
$513.8M
Enterprise value
$225.44M
Price to book (P/B)
1.98
Price to sales (P/S)
3.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.38
Revenue
$163.87M
EBIT
-$81.45M
EBITDA
-$78M
Free cash flow
-$71.16M
Per share
Balance sheet
Liquidity
EPS
-$2.69
Free cash flow per share
-$2.64
Book value per share
$9.6
Revenue per share
$6.08
TBVPS
$14.41
Total assets
$388.61M
Total liabilities
$130.03M
Debt
$26.96M
Equity
$258.58M
Working capital
$255.29M
Debt to equity
0.1
Current ratio
3.78
Quick ratio
3.7
Net debt/EBITDA
3.7
Margins
Efficiency
Dividend
EBITDA margin
-47.6%
Gross margin
100%
Net margin
-43.9%
Operating margin
-54.4%
Return on assets
-17%
Return on equity
-26.6%
Return on invested capital
-351.9%
Return on capital employed
-27.4%
Return on sales
-49.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARCT stock price
How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-5%
1 week
-7.77%
1 month
-12.6%
1 year
-4.33%
YTD
-39.74%
QTD
-18.14%
Financial performance
How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$163.87M
Gross profit
$163.87M
Operating income
-$89.12M
Net income
-$71.96M
Gross margin
100%
Net margin
-43.9%
The net income has dropped by 190% year-on-year but it is up by 33% since the previous quarter
Arcturus Therapeutics Holdings's net margin has increased by 49% QoQ
Arcturus Therapeutics Holdings's operating margin has increased by 45% QoQ
The revenue has declined by 38% year-on-year but it has grown by 32% since the previous quarter
Growth
What is Arcturus Therapeutics Holdings's growth rate over time
Valuation
What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
1.98
P/S
3.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.38
The company's EPS has shrunk by 188% YoY but it rose by 33% QoQ
ARCT's P/B is 51% lower than its 5-year quarterly average of 4.0 and 32% lower than its last 4 quarters average of 2.9
ARCT's equity is down by 9% year-on-year and by 2% since the previous quarter
ARCT's price to sales (P/S) is 93% lower than its 5-year quarterly average of 43.0 and 33% lower than its last 4 quarters average of 4.7
The revenue has declined by 38% year-on-year but it has grown by 32% since the previous quarter
Efficiency
How efficient is Arcturus Therapeutics Holdings business performance
The ROA has shrunk by 187% YoY but it has increased by 31% QoQ
The company's return on equity has shrunk by 185% YoY but it rose by 31% QoQ
The company's return on sales rose by 47% QoQ
Arcturus Therapeutics Holdings's ROIC has increased by 44% from the previous quarter
Dividends
What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARCT.
Financial health
How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total assets is 199% higher than its total liabilities
ARCT's current ratio is up by 16% QoQ but it is down by 11% YoY
Arcturus Therapeutics Holdings's total liabilities has decreased by 16% QoQ and by 11% YoY
Arcturus Therapeutics Holdings's debt is 90% lower than its equity
ARCT's equity is down by 9% year-on-year and by 2% since the previous quarter
Arcturus Therapeutics Holdings's debt has decreased by 4.1% YoY and by 2.5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.